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Introduction {#sec001}
============

Antibiotics are of immense value for fighting bacterial infections, however, their effectiveness has been threatened by the continuing emergence of bacteria resistant to these drugs \[[@pone.0172273.ref001]\], becoming the main cause of failure in the treatment of infectious diseases \[[@pone.0172273.ref002]\]. Currently, there are more than 15 kinds of antibiotics whose action sites are related to physiological or metabolic functions essential for the bacteria. Unfortunately, none have escaped the resistance phenomenon \[[@pone.0172273.ref003]\], increasing the number of pathogenic bacteria that show a phenotype of resistance to multiple antibiotics (MDR), as for example methicillin resistant *Staphylococcus aureus* (MRSA) and *Escherichia coli* clinical isolates \[[@pone.0172273.ref001], [@pone.0172273.ref004]\]. It is for these reasons that new alternatives need to be sought. One strategy dealing this problem is the synergy using combinations of natural compounds with antibiotics and thus enhancing or restoring the antibacterial activity of many antibiotics currently useless because of bacterial resistance mechanisms acquisition.

Different combinations may improve or facilitate the interaction of an antibiotic with its target inside the bacterial cell, and in addition, some compounds should act by a different mechanism as the known antibacterial agent. The synergy can be used to expand the antimicrobial spectrum, prevent the emergence of antibiotic resistant bacteria, and to minimize toxicity, since lower concentrations of both agents can be used. Many *in vitro* studies have been published which show the synergistic effect between plant extracts with antibiotics of different classes against sensitive and multi-drug resistant pathogenic strains. Betoni et al. \[[@pone.0172273.ref005]\] showed that plants possess antibacterial compounds that may act in synergy by sensitizing the pathogen to the antibiotic. Moreover, several studies have found that the combination of antimicrobial agents with plant extracts reduced the minimum inhibitory concentration of antibiotics in different MDR bacteria \[[@pone.0172273.ref006]--[@pone.0172273.ref008]\].

A rich resource of phenolic compounds is the grape pomace (*Vitis vinifera*), which is the main organic waste generated in the industries of wine \[[@pone.0172273.ref009]\] representing between 13--20% of the total weight of the processed grapes \[[@pone.0172273.ref010]\]. The phenolic compounds content in pomace includes phenolic acids (gallic, sinapic, protocatechuic, etc.), and flavonoids as flavan-3-ol such as (+)-catechin, (-)-epicatechin, (-)-epicatechin-3-O-gallate, quercetin, miricetin, kaempferol, luteolin, among others \[[@pone.0172273.ref011], [@pone.0172273.ref012]\].

The antibacterial activity of the phenolic compounds identified in grape has been studied in extracts obtained from fruits \[[@pone.0172273.ref013]\], seeds \[[@pone.0172273.ref014]--[@pone.0172273.ref016]\], skin \[[@pone.0172273.ref017]\] and pomace \[[@pone.0172273.ref015], [@pone.0172273.ref018], [@pone.0172273.ref019]\]. Moreover, it has been determined that phenolic compounds act in synergy with different classes of antibiotics \[[@pone.0172273.ref020]--[@pone.0172273.ref022]\]. Some examples are epicatechin gallate (EGC) and epigallocatechin gallate (EGCg), able to reduce 64 times the MIC of oxacillin MRSA strains \[[@pone.0172273.ref023]\], as well as baicalein with tetracyclines and β-lactamics \[[@pone.0172273.ref024]\]. Furthermore, curcumin acts in synergy with β-lactamics reducing the MIC of oxacillin and ampicillin16 times, and 25 times the MIC of ciprofloxacin \[[@pone.0172273.ref025]\]. Within the mechanisms by which the phenolic compounds exert their antibacterial effect, it is described that are capable of interacting with the cytoplasmic membrane, cell wall, nucleic acids and/or energy transport \[[@pone.0172273.ref002]\], altering or inhibiting their functions.

In this study, the synergy between grape pomace extracts with antibiotics from different classes was determined against multi-resistant clinical isolates of *S*. *aureus* and *E*. *coli*. In addition, it was evaluated if pure phenolic compounds present in grape pomace extracts exert this synergistic effect and cytotoxicity determination of synergic combinations was also included.

Materials and methods {#sec002}
=====================

Grape pomace extract {#sec003}
--------------------

The grape pomace of Cabernet Sauvignon variety was obtained from Viña Miguel Torres (Curicó, Chile). Samples (900 g) were ground and extracted with methanol/HCl 1% (v/v) for 18 h at 4°C under constant agitation (100 rpm). Samples were concentrated on a rotary evaporator at 50°C and subjected to liquid-liquid extraction with ethyl acetate \[[@pone.0172273.ref012]\]. Finally, the samples were concentrated to dryness and kept at -20°C.

Compounds identification by chromatographic analysis {#sec004}
----------------------------------------------------

Phenolic compounds present in the grape pomace extract were separated through RP-HPLC as described by Mendoza et al. \[[@pone.0172273.ref012]\] using a Waters 600 HPLC chromatograph (Waters, Mildford, MA, USA) equipped with a Waters 2990 diode detector and a C-18 column (3,9 mm x 150 mm; Waters, Mildford, MA, USA). A gradient program consisting of solvent A (acetic acid 1% (v/v) in distilled water) and solvent B (acetonitrile 100%) was applied at a flow rate of 0.8 mL/min as follows: a linear gradient of 10 to 20% B in 20 min; this proportion was maintained for the following 20 min; and then, a linear gradient from 20 to 50% B in 5 min; this last proportion was maintained up to 60 min. Grape pomace extract and individual phenolic compounds were prepared at 5 mg/mL in 1 mL methanol and 20 μL of sample solution was injected. The detector was set at 280 and 360 nm. Identification of phenolic compounds was done by comparison of UV---vis spectra and retention times with standards using Millenium 3.20 software. All standards, gallic acid, protocatechuic acid, syringic acid, vanillic acid, p-coumaric acid, ellagic acid, kaempferol, quercetin, luteolin, (+)-catechin and (-)-epicatechin, were obtained from Sigma Aldrich. Each sample was analyzed in triplicate.

Bacterial strains and culture media {#sec005}
-----------------------------------

Five clinical isolates of *S*. *aureus*, strains 8298--2, 8275, and methicillin-resistant *S*. *aureus* (MRSA) strains 622--4, and 97--7, kindly donated by Dr. Gino Corsini (Universidad Autónoma, Chile) were used; and as a control strain, *S*. *aureus* ATCC 6538. For *E*. *coli*, three clinical isolates (33.1, 16.1 and A2UC, kindly donated by the Instituto de Salud Pública de Chile; and the control *E*. *coli* ATCC 25922 were used. All strains were cultured on Luria-Bertani (LB) agar and incubated at 37°C for 18--24 h.

Antibiotic sensitivity assays {#sec006}
-----------------------------

Antibiotic susceptibility of all bacterial strains was determined following the disc agar diffusion assay described by Clinical Laboratory Standards (CLSI) \[[@pone.0172273.ref026]\]. The bacterial strains were cultured overnight, diluted in Mueller Hinton (MH) broth to a McFarland turbidity of 0.5 (1 x 10^8^ colony forming unit (CFU)/mL) and seeded homogeneously on Petri dishes containing Mueller Hinton agar. Sterile discs containing different concentrations of antibiotics were placed on the inoculated agar. After incubation for 18 h at 37°C, the inhibition diameters were measured and these values in millimeter (mm) were interpreted according to the criteria established by CLSI as resistant (R) or sensitive (S). Antibiotics used for *S*. *aureus* susceptibility determination were nalidixic acid (30 μg), oxacillin (1 μg), ciprofloxacin (5 μg), norfloxacin (10 μg), levofloxacin (5 μg) tetracycline (30 μg), and chloramphenicol (30 μg). The same antibiotics were used for *E*. *coli*, except that the oxacillin was replaced with ampicillin (10 μg).

Minimal inhibitory concentration determination {#sec007}
----------------------------------------------

Minimal inhibitory concentration (MIC) of four different classes of antibiotics against all used strains was determined. As representative of the β-lactam class, oxacillin and ampicillin; nalidixic acid for quinolone; the fluoroquinolones class represented by ciprofloxacin, norfloxacin and levofloxacin; tetracycline representing tetracycline family; and finally, chloramphenicol as representative of the antibiotic class amphenicol. All these drugs were obtained from Sigma Aldrich. The MIC was also determined for grape pomace extract and the following phenolic compounds identified in pomace in this work as gallic acid, syringic acid, vanillic acid, quercetin, kaempferol, luteolin, (+)-catechin, and (-)-epicatechin.

For all the above-mentioned drugs, compounds and extract, the MIC determination assay was followed as established by CLSI using the micro-broth dilutions method in 96-well plates (Nunc) at different concentration ranges. To each well, 188 μL of MH broth, 10 μL of pomace extract (300 to 3,000 μg/mL diluted in dimethyl sulfoxide (DMSO)), antibiotic (0.75 to 3,000 μg/mL) or pure phenolic compound (200 to 10,000 μg/mL diluted in DMSO), and finally 2 μL bacterial suspension at McFarland 0.5 (1 x 10^8^ CFU/mL) to complete a final volume of 200 μL. In addition, some wells were used as solvent and sterility controls. The plates were incubated at 37°C for 24 h and the optical density was measured at 600 nm in an Elisa lector (Thermos Labsystems Multiskan FC Model). Results are expressed in μg/mL and all experiments were done in triplicates in three individual experiments.

Checkerboard assays {#sec008}
-------------------

Synergy between grape pomace extract and 8 different antibiotics, as well as between grape pomace extract and 10 pure phenolic components identified therein were evaluated by the checkerboard method described by Motyl et al. \[[@pone.0172273.ref027]\] with minor modifications. Results of the combination between pure compounds and the whole extract should give a clue which component is responsible of the synergic effect against the multi-resistant clinical isolates and control strains. Briefly, eight serial, twofold dilutions of grape pomace extract and antibiotic were prepared. In a 96-well plate, 25 μL of each dilution of grape pomace extract was added in each vertical row, and 25 μL of antibiotic or pure compound dilution was added in each horizontal row. Both first horizontal and vertical rows were left with only one agent and the following rows contained a fixed amount of one agent and increasing concentrations of the second agent. In the selection of the range of concentrations, the MICs obtained for each tested agent and tested bacteria were considered. Grape pomace extract concentrations used ranged from 47 to 3,000 μg/mL and 3 to 3,000 μg/mL for antibiotic. To each well, 100 μL of MH broth and 10 μL bacterial suspension (1 x 10^8^ CFU/mL) were added. The plates were incubated at 37°C for 24 h and measured at 600 nm in an Elisa lector (Thermos Labsystems Multiskan FC Model). All tests were performed in triplicate in three different experiments. Fractional inhibitory concentrations (FIC) were calculated by the formula FIC~extract~ = (MIC extract + antibiotic / MIC extract) or FIC~antibiotic~ = (MIC extract + antibiotic / MIC antibiotic). The FIC index (FICI; \[[@pone.0172273.ref003]\]) for each combination was calculated by the sum of both FIC values, and results were interpreted as follows: FICI ≤ 0.5 synergic effect, 0.5 \< FICI ≤ 4 additive effect and FICI ˃ 4 antagonistic effect \[[@pone.0172273.ref003]\]. These same formula were used for the calculation of the combinations of grape pomace extract with each phenolic compound.

Cytotoxicity {#sec009}
------------

In order to determine the cytotoxic potential of the synergistic combinations between grape pomace extract with antibiotics of different types, the cervical cancer cell line HeLa (ATCC CCL-2, USA) was used.

### HeLa cell line culture {#sec010}

HeLa cells were grown in Dulbecco\'s modified medium (DMEM; Corning, USA) with bovine fetal serum 10% (FBS) supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin (Corning Eagle, USA) in a modified Thermo Scientific air incubator (5% CO~2~ at 37°C). The medium was renewed every 2 days to reach 80% confluence, then the cells were transferred to T75 flasks, grown to reach 80% confluence, and finally the culture was divided into sterile 24-well plates.

### Cytotoxicity evaluation {#sec011}

Approximately 10,000 cells per well in a 24-well plate were seeded in 100 μL of DMEM. The cells were treated with different concentrations of the grape pomace extract (750, 375, 188, 94 and 47 μg/mL, in 20 μL DMSO). Simultaneously, growth controls were performed, which consisted of cells incubated with culture medium alone and with 20 μL DMSO as solvent control. Finally, treated HeLa cells and the respective controls were incubated for 24 h in 5% CO~2~ at 37°C. All tests were carried out in triplicate. This same procedure was performed with the combinations between grape pomace extracts and the representatives of different classes of antibiotics that showed a synergistic effect at the minimal concentration. Concentrations used for ciprofloxacin and chloramphenicol were 20, 10, 5, 2.5, 1.25 and 0.62 μg/mL, for ampicillin were 750, 375, 188, 94, 47 and 23 μg/mL, while the concentration of grape pomace extract was 47 μg/mL, the lowest concentration that showed synergic effect. Cell viability was determined using propidium iodide as a marker of dead cells at a concentration of 1 μg/mL. Samples were analyzed on a FACSCanto II flow cytometer (Becton Dickinson). The analysis of the results was performed using the FACSDiva software.

Statistical analysis {#sec012}
--------------------

All data were analyzed using t-test using Graph Pad Prism 5 software.

Results and discussion {#sec013}
======================

Minimum inhibitory concentration {#sec014}
--------------------------------

Results of the susceptibility tests for *S*. *aureus* and *E*. *coli* strains are shown in Tables [1](#pone.0172273.t001){ref-type="table"} and [2](#pone.0172273.t002){ref-type="table"}, respectively. The clinical isolates used in this study were resistant to more than three classes of antibiotics according to the criteria stablished by CLSI. This indicates that all isolates of both *S*. *aureus* and *E*. *coli* should be classified as multidrug resistant bacteria \[[@pone.0172273.ref028]\]. Even more, *S*. *aureus* isolates 8298--2 and 97--7 MRSA were resistant to all classes of antibiotics studied (fluoroquinolones, β-lactams, amphenicols and tetracyclines), while *E*. *coli* clinical isolates 16.1 and 33.1 showed the same trend. Three of the four *S*. *aureus* isolates and all *E*. *coli* were resistant to tetracycline. For chloramphenicol, three *S*. *aureus* and two *E*. *coli* isolates showed resistance to this drug. The minimum inhibitory concentrations (MIC) determined for each antibiotic by microdilution broth method are also shown in Tables [1](#pone.0172273.t001){ref-type="table"} and [2](#pone.0172273.t002){ref-type="table"}. MIC values were high for all clinical isolates compared to the respective control strain. This tendency was similar for the MICs values obtained with the grape pomace extract, ranging between 1,500 to 3,000 μg/mL with the clinical isolates, compared to MIC values of 600 and 300 μg/mL obtained with the control strains *S*. *aureus* ATCC 6538 and *E*. *coli* ATCC 25922, respectively.

10.1371/journal.pone.0172273.t001

###### Synergy analysis of grape pomace extract with different antibiotics against *S*. *aureus*.

![](pone.0172273.t001){#pone.0172273.t001g}

                                             MIC (μg/mL)                       
  ----------------- ---------------- ------- ------------- ------ ------- ---- -------
  **ATCC 6538**     Nalidixic acid   \(R\)   60            600    0.93    65   0.078
  Ciprofloxacin                      1.5     0.02          75     0.028        
  Norfloxacin                        1.5     0.02          75     0.078        
  Levofloxacin                       1.5     0.02          75     0.078        
  Oxacillin                          3       0.05          64     0.047        
  Tetracycline                       1.5     0.05          30     0.094        
  Chloramphenicol                    16      0.25          64     0.047        
  **8275**          Nalidixic acid   \(R\)   300           1500   4.7     64   0.065
  Ciprofloxacin     \(R\)            30      0.9           32     0.062        
  Norfloxacin       \(R\)            25      0.8           32     0.047        
  Levofloxacin                       10      0.3           33     0.047        
  Oxacillin         \(R\)            50      1.6           31     0.063        
  Tetracycline                       5       0.08          63     0.047        
  Chloramphenicol   \(R\)            75      2.3           33     0.062        
  **8298--2**       Nalidixic acid   \(R\)   200           1500   6.2     32   0.062
  Ciprofloxacin     \(R\)            150     4.7           32     0.063        
  Norfloxacin       \(R\)            300     9.4           32     0.047        
  Levofloxacin      \(R\)            20      0.31          65     0.031        
  Oxacillin         \(R\)            300     4.7           64     0.031        
  Tetracycline      \(R\)            8       0.25          32     0.047        
  Chloramphenicol   \(R\)            150     4.7           32     0.047        
  **MRSA**          Nalidixic acid   \(R\)   300           3000   4,7     64   0.047
  Ciprofloxacin     \(R\)            15      0.5           30     0.063        
  Norfloxacin       \(R\)            30      0.5           60     0.047        
  Levofloxacin                       3       0.1           30     0.061        
  Oxacillin         \(R\)            150     2.3           65     0.047        
  Tetracycline      \(R\)            750     23            33     0.062        
  Chloramphenicol                    1       0.02          50     0.056        
  **MRSA**          Nalidixic acid   \(R\)   150           1500   4.7     32   0.063
  Ciprofloxacin     \(R\)            50      1.6           31     0.063        
  Norfloxacin       \(R\)            25      0.8           31     0.063        
  Levofloxacin      \(R\)            8       0.25          32     0.063        
  Oxacillin         \(R\)            300     4.6           65     0.047        
  Tetracycline      \(R\)            500     7.8           64     0.047        
  Chloramphenicol   \(R\)            5       0.16          31     0.063        

\*The susceptibility to antibiotics is indicated only if the bacterial strain is resistant (R).

10.1371/journal.pone.0172273.t002

###### Synergy analysis of grape pomace extract with different antibiotics against *E*. *coli*.

![](pone.0172273.t002){#pone.0172273.t002g}

                                             MIC (μg/mL)                       
  ----------------- ---------------- ------- ------------- ------ ------- ---- -------
  **ATCC 25922**    Nalidixic acid   \(R\)   16            300    0.25    64   0.078
  Ciprofloxacin                      1       0.03          33     0.155        
  Norfloxacin                        1.5     0.045         33     0.155        
  Levofloxacin                       0.75    0.02          38     0.093        
  Ampicillin        \(R\)            15      0.47          32     0.063        
  Tetracycline                       3       0.05          60     0.078        
  Chloramphenicol                    8       0.12          67     0.078        
  **16.1**          Nalidixic acid   \(R\)   2000          1500   31.2    64   0.047
  Ciprofloxacin     \(R\)            150     4.7           32     0.063        
  Norfloxacin       \(R\)            200     3.1           65     0.031        
  Levofloxacin      \(R\)            50      1.6           31     0.063        
  Ampicillin        \(R\)            1500    47.0          32     0.063        
  Tetracycline      \(R\)            100     3.1           32     0.047        
  Chloramphenicol   \(R\)            10      0.3           33     0.062        
  **33.1**          Nalidixic acid   \(R\)   3000          3000   95.0    32   0.047
  Ciprofloxacin     \(R\)            20      1.25          16     0.078        
  Norfloxacin       \(R\)            20      1.25          16     0.078        
  Levofloxacin      \(R\)            30      0.47          64     0.047        
  Ampicillin        \(R\)            1500    23.4          64     0.047        
  Tetracycline      \(R\)            150     9.4           16     0.078        
  Chloramphenicol   \(R\)            15      0.47          32     0.078        
  **A2UC**          Nalidixic acid   \(R\)   150           3000   4.7     32   0.047
  Ciprofloxacin     \(R\)            3       0.05          60     0.032        
  Norfloxacin       \(R\)            6       0.2           30     0.063        
  Levofloxacin                       1.5     0.05          30     0.065        
  Ampicillin        \(R\)            62      15            4      0.281        
  Tetracycline      \(R\)            150     9.4           16     0.094        
  Chloramphenicol                    10      0.16          63     0.047        

\*The susceptibility to antibiotics is indicated only if the bacterial strain is resistant (R).

Synergy interactions analysis {#sec015}
-----------------------------

All combinations of grape pomace extract with the different classes of antibiotics were tested against each of the described clinical isolates of both *S*. *aureus* and *E*. *coli*. As shown in [Table 1](#pone.0172273.t001){ref-type="table"}, against *S*. *aureus* isolates and the ATCC strain, a significant decrease of the MICs of all drugs was observed when the antibiotics were combined with the grape pomace extract reaching 30 to 75 times fold reduction, regardless if bacteria tested was or not resistant to the antibiotic.

FICI values obtained in the checkerboard assays were in the range of 0.03 to 0.094, indicating that all combinations studied have a synergistic effect (FICI ≤ 0.5) in all isolates, regardless of the mechanism of action of the tested antibiotic. Very similar results were observed in *E*. *coli* clinical isolates and the control strain ([Table 2](#pone.0172273.t002){ref-type="table"}), in which the extract combinations with antibiotics (β-lactams, quinolones, tetracycline and chloramphenicol) showed reductions in the MIC of 4 to 67 times. Regarding FICI values, these ranged from 0.03 to 0.15, indicating that all tested combinations are synergistic. These results coincide with those reported in the literature in the sense that combinations of plant extracts with antibiotics belonging to different families show synergy against clinical isolates of *S*. *aureus* (MSSA, MRSA) and *E*. *coli*, significantly reducing the MIC of all antibiotics tested \[[@pone.0172273.ref008], [@pone.0172273.ref029]\]. *Camellia sinensis* extracts, particularly rich in polyphenols, when combined with oxacillin, decreased the MIC 256 times (from 256 μg/mL to 1 μg/mL) against MRSA strains \[[@pone.0172273.ref006]\]. Furthermore, this extract was able to potentiate the activity of levofloxacin *in vivo* against enterohemorrhagic *E*. *coli* O157 \[[@pone.0172273.ref030]\]. Our results indicate that the effect observed in all pomace extract---antibiotics combinations is independent of the mechanism of action of the antibiotic used, if the strain was resistant or not, and indifferent if bacteria is Gram-positive *S*. *aureus* or Gram-negative *E*. *coli*.

As grape is rich in phenolic compounds \[[@pone.0172273.ref011]\], their identification in the pomace extract should give a clue to determine which compound is responsible for the observed synergistic effect. [Table 3](#pone.0172273.t003){ref-type="table"} shows the list of 11 compounds identified in the extract with their relative abundance; 5 phenolic acids identified as gallic, syringic, vanillic, protocatechuic and p-coumaric, 5 flavonoids identified as quercetin, luteolin, kaempferol, (+)-catechin and (-)-epicatechin; and 1 tanin identified as ellagic acid. Different separation methods have been used for the identification of phenolic compounds in different *V*. *vinifera* varieties. Nicoletti et al. \[[@pone.0172273.ref031]\] analyzed nine grape varieties using RP-HPLC-MS and identified gallic acid, protocatechuic acid, catechin, epicatechin, rutin, among others. Sagdic et al. \[[@pone.0172273.ref032]\] determined the presence of 18 different phenolic compounds, including gallic acid, protocatechuic acid, p-coumaric acid, ferulic acid, vanillic acid, quercetin, kaempferol, (+)-catechin, (-)-epicatechin, hesperidin, among others, in 5 grape varieties cultivated in Greece. Similar results with different techniques based on HPLC were obtained by Kammerer et al. \[[@pone.0172273.ref033]\], Lafka et al. \[[@pone.0172273.ref034]\], Rockenbach et al. \[[@pone.0172273.ref009]\], and Mendoza et al. \[[@pone.0172273.ref012]\].

10.1371/journal.pone.0172273.t003

###### Relative abundance of phenolic compounds in grape pomace extract.

![](pone.0172273.t003){#pone.0172273.t003g}

  Compounds             Retention time (min)   λ (nm)         Relative abundance (%)
  --------------------- ---------------------- -------------- ------------------------
  Quercetin             52.1                   255.5--369.3   26.3
  Gallic acid           5.1                    227.2--272.0   24.4
  Protocatechuic acid   9.2                    224.9--260.2   16.7
  Luteolin              54.8                   253.3--246.8   11.4
  (+)-Catechin          13.5                   228.4--279.1   3.7
  (-)-Epicatechin       18.6                   227.2--279.1   3.7
  Vanillic acid         17.6                   261.4--293.3   2.7
  Kaempferol            53.8                   266.1--365.7   2.4
  Syringic acid         18.1                   226.1--275.6   2.3
  p-Coumaric acid       25.7                   227.2--309.9   2.1
  Ellagic acid          27.6                   254.3--366.9   1.6

The relative abundance of the phenolics present in the grape pomace extract showed that gallic acid was the major component with a relative abundance of 26.3%, followed by protocatechuic acid, quercetin and luteolin (24.4, 16.7 and 11.4%, respectively; [Table 3](#pone.0172273.t003){ref-type="table"}). The major components identified by Sadgic et al. \[[@pone.0172273.ref032]\] were gallic acid, chlorogenic acid, (+)-catechin, kaempferol, rutin and quercetin, results that are similar to those obtained in this work.

Considering the identification of phenolic compounds in the extract, checkerboard assays were performed between grape pomace extract and pure phenolic compounds to answer the question, which compound is responsible for the observed synergic effect, if the relative abundance is or not relevant, or the synergy effect is due to the presence of all components in the extract.

Tables [4](#pone.0172273.t004){ref-type="table"} and [5](#pone.0172273.t005){ref-type="table"} show the results obtained from the synergism analysis between grape pomace extract with each phenolic compound with *S*. *aureus* and *E*. *coli* strains, respectively. The MIC values of each of the phenolic compounds identified in the extract are high against both bacteria, including their respective control strains. For the pure phenolic acids (gallic, vanillic, syringic, p-coumaric and protocatechuic), the MIC ranged from 300 to 3,000 μg/mL for *S*. *aureus* and between 500 to 4,000 μg/mL for *E*. *coli*. The MICs obtained in the analysis of pure flavonoids (quercetin, luteolin, (-)-epicatechin and ellagic acid) ranged between 100 to 600 and 100 to 3,000 μg/mL for *S*. *aureus* and *E*. *coli*, respectively. In the case of (+)-catechin, MIC values were higher than 10,000 μg/mL in all isolates tested, indicating that it is inactive. Importantly, between control strains and the clinical isolates studied, no large differences were observed in the MICs for the identified phenolic compounds, either phenolic acids or flavonoids. Despite the high MIC values for the purified phenolic compounds, the combination of these compounds with the pomace extract reduced the MIC considerably, between 8 to 65 times for *S*. *aureus* and between 4 to125 times for *E*. *coli*.

10.1371/journal.pone.0172273.t004

###### Synergy analysis between grape pomace extract and pure phenolic compounds in *S*. *aureus*.

![](pone.0172273.t004){#pone.0172273.t004g}

                                              MIC (μg/mL)                  
  --------------------- --------------------- ------------- ------ ------- --------
  ATCC 6538             Gallic acid           1500          47     32      0.094
  Vanillic acid         1000                  31.2          32     0.063   
  Syringic acid         625                   39            16     0.125   
  p-Coumaric acid       1500                  24            63     0.047   
  Protocatechuic acid   750                   23            33     0.093   
  Ellagic acid          500                   16            31     0.048   
  Quercetin             375                   11.7          32     0.063   
  Luteolin              100                   3.1           32     0.047   
  (+)-Catechin          ˃ 10000               \-            \-     \-      
  (-)-Epicatechin       500                   62.5          8      0.162   
  8275                  Gallic acid           1500          24     63      0.032
  Vanillic acid         1500                  47            32     0.061   
  Syringic acid         750                   24            31     0.060   
  p-Coumaric acid       300                   9.4           32     0.060   
  Protocatechuic acid   750                   24            31     0.048   
  Ellagic acid          250                   15.6          16     0.094   
  Quercetin             600                   9.4           64     0.032   
  Luteolin              500                   31.2          16     0.094   
  (+)-Catechin          ˃ 10000               \-            \-     \-      
  (-)-Epicatechin       1000                  15.6          64     0.047   
  8298--2               Gallic acid           3000          94     32      0.063
  Vanillic acid         1500                  47            32     0.063   
  Syringic acid         3000                  47            64     0.047   
  p-Coumaric acid       750                   47            16     0.078   
  Protocatechuic acid   750                   24            31     0.063   
  Ellagic acid          125                   15.6          8      0.168   
  Quercetin             150                   4.7           32     0.063   
  Luteolin              500                   31.2          16     0.094   
  (+)-Catechin          ˃10000                \-            \-     \-      
  (-)-Epicatechin       1000                  15.6          64     0.047   
                        Gallic acid           3000          47     64      0.047
                        Vanillic acid         1500          47     32      0.063
                        Syringic acid         1500          47     32      0.047
                        p-Coumaric acid       1500          47     32      0.063
  MRSA                  Protocatechuic acid   750           47     16      0.094
  622--4                Ellagic acid          250           3.9    64      0.031
                        Quercetin             300           9.4    32      0.063
                        Luteolin              500           7.8    64      0.031
                        (+)-Catechin          ˃10000        \-     \-      \-
                        (-)-Epicatechin       1000          15.6   64      0.031
                        Gallic acid           2000          31     65      0.047
                        Vanillic acid         1500          47     32      0.063
                        Syringic acid         750           24     31      0.047
                        p-Coumaric acid       750           24     31      0.047
  MRSA                  Protocatechuic acid   750           24     32      0.047
  97--7                 Ellagic acid          62.5          7.8    8       0.187
                        Quercetin             100           3.1    32      0.062
                        Luteolin              1000          62.5   16      0.093
                        (+)-Catechin          ˃10000        \-     \-      \-
                        (-)-Epicatechin       500           16     31      -0.063

10.1371/journal.pone.0172273.t005

###### Synergy analysis between grape pomace extract and pure phenolic compounds in *E*. *coli*.
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                                      MIC (μg/mL)                  
  --------------------- ------------- ------------- ------ ------- -------
  ATCC 25922            Gallic acid   2000          16     125     0.047
  Vanillic acid         750           23            32     0.089   
  Syringic acid         1000          16            63     0.078   
  p-Coumaric acid       750           47            16     0.125   
  Protocatechuic acid   1000          16            63     0.078   
  Ellagic acid          1000          62.5          16     0.094   
  Quercetin             500           62.5          8      0.188   
  Luteolin              200           25            8      0.156   
  (+)-Catechin          ˃10000        \-            \-     \-      
  (-)-Epicatechin       1000          125           8      0.188   
  16.1                  Gallic acid   2000          62.5   32      0.063
  Vanillic acid         1000          62.5          16     0.125   
  Syringic acid         500           62.5          8      0.141   
  p-Coumaric acid       1000          62.5          16     0.125   
  Protocatechuic acid   2000          62.5          32     0.063   
  Ellagic acid          1000          250           4      0.281   
  Quercetin             3000          375           8      0.156   
  Luteolin              300           18.8          16     0.094   
  (+)-Catechin          ˃10000        \-            \-     \-      
  (-)-Epicatechin       3000          750           4      0.313   
  33.1                  Gallic acid   2500          150    16      0.076
  Vanillic acid         4000          250           16     0.185   
  Syringic acid         750           47            16     0.078   
  p-Coumaric acid       1000          125           8      0.156   
  Protocatechuic acid   4000          1000          4      0.500   
  Ellagic acid          200           6.25          32     0.047   
  Quercetin             500           15.6          32     0.062   
  Luteolin              300           18.8          16     0.094   
  (+)-Catechin          ˃10000        \-            \-     \-      
  (-)-Epicatechin       3000          750           4      0.266   
  A2UC                  Gallic acid   1500          94     16      0.078
  Vanillic acid         2000          62.5          32     0.047   
  Syringic acid         1500          24            63     0.032   
  p-Coumaric acid       2000          62.5          32     0.219   
  Protocatechuic acid   2000          62.5          32     0.052   
  Ellagic acid          500           31.2          16     0.156   
  Quercetin             3000          188           16     0.078   
  Luteolin              250           7.8           32     0.047   
  (+)-Catechin          ˃10000        \-            \-     \-      
  (-)-Epicatechin       5000          625           8      0.250   

The fractional inhibitory concentration index (FICI) analysis by the checkerboard method showed for all combinations and bacterial isolates tested, values below 0.5, which is indicative of synergy (Tables [4](#pone.0172273.t004){ref-type="table"} and [5](#pone.0172273.t005){ref-type="table"}). Results show that FICI values have no correlation with the relative abundance of the compounds in the extract ([Table 3](#pone.0172273.t003){ref-type="table"}), since gallic acid, one of the most abundant compound identified presented FICI values between 0.032--0.094 for *S*. *aureus* and *E*. *coli*, similar range compared to the results of less abundant compounds like vanillic, syringic and p-coumaric acids, which FICI values range between 0.031 to 0.185 with all bacteria tested. These results suggest that it is not only one compound that is responsible for the observed synergistic effect, but that each of the identified compounds contributes to this effect to a greater or lesser extent (all combinations showed synergy), resulting in a multi-objective effect of grape pomace extract. This is strongly suggested by the synergy obtained when the extract was combined with antibiotics of different kinds, regardless of their mechanism of action.

Furthermore, it has been described that phenolic acids can break down the structure of the cytoplasmic membrane causing loss of integrity and eventual cell death \[[@pone.0172273.ref002], [@pone.0172273.ref035]\]. At sub-inhibitory concentrations, the compounds present in the extract would facilitate the entrance of the antibiotic to the cell cytoplasm, thus facilitating the entrance of fluoroquinolones, tetracycline and chloramphenicol, which have their site action within the bacterial cell, and less antibiotic dose would be needed. In this way, the multi-objective mechanism would be accomplished by disrupting the cytoplasmic membrane and some vital function as DNA replication, transcription or translation processes, depending on the antibiotic used.

Flavonoids has been described as causing cytoplasmic membrane damage, inhibition of peptidoglycan synthesis, nucleic acids synthesis inhibition, and/or energy transport inhibition \[[@pone.0172273.ref002]\]. Within the grape pomace extract, flavonoids luteolin, kaempferol, quercetin, (+)-catechin and (-)-epicatechin were identified. Cushnie and Lamb \[[@pone.0172273.ref036]\] determined the mechanism of action for (+)-catechin by cytoplasmic membrane damage, causing direct disruption of the lipid bilayers and alteration of the barrier function. Quercetin has also been shown that causes an increase in the permeability of the cytoplasmic membrane and dissipation of the membrane potential \[[@pone.0172273.ref022], [@pone.0172273.ref036]\]. Quercetin showed the highest relative abundance in our grape pomace extract. On the other hand, it has been described that flavonoids as corilagin and tellimagrandin I inhibit penicillin binding proteins (PBPs), specifically PBP2\`(PBP2a) in methicillin resistant *S*. *aureus* (MRSA; \[[@pone.0172273.ref037]\]). This evidence support our results of synergy, compounds in grape pomace extract would interact with PBPs decreasing the effective concentration of β-lactamic antibiotics. Preliminary results obtained in our laboratory showed that grape pomace extract inhibits β-lactamases in *S*. *aureus* and *E*. *coli* (data not shown). It was also published that luteolin identified in grape pomace extract, increased the efficacy of different antibiotics, since it inhibits β-lactamase in MDR *E*. *coli* strains \[[@pone.0172273.ref021]\], affected the cytoplasmic membrane stability (possibly by generating hydrogen peroxide); inhibited enzymes involved in the synthesis of folic acid as dihydrofolate reductase \[[@pone.0172273.ref038]\]. These facts support a multi-target mechanism determined by the extract components. Therefore, the extract components could act at different targets increasing the susceptibility of bacteria and enhancing the activity of antibiotics, which result in significant reductions in the MIC of antibiotics.

However, it is important to highlight that even the grape has high concentration of phenolic compounds, it also contains other class of compounds like terpenes among which uvaol, β-amirin, palmitic acid, eicosanol, scualene and estearic acid were identified (data not shown). Antibacterial activity for these terpenes was also demonstrated \[[@pone.0172273.ref039], [@pone.0172273.ref040]\], suggesting that they could also contribute to the synergy effect.

Cytotoxicity {#sec016}
------------

The toxicity evaluation of grape pomace extract on HeLa cells is shown in [Fig 1](#pone.0172273.g001){ref-type="fig"}, indicating that the cell viability at low concentrations (23--188 μg/mL) is not affected compared to the control (98.3%) with viability percentages in a range of 98.4--97.4%. However, at higher concentrations (375 and 750 μg/mL), the viability was reduced to 95.4 and 94.4%, respectively. From these results, it can be concluded that the cytotoxicity of grape pomace extract increases with concentration. This result has been previously reported with plant extracts with high content of phenolic compounds \[[@pone.0172273.ref041], [@pone.0172273.ref042]\].

![Viability of HeLa cells exposed to different concentrations of grape pomace extract.\
HeLa cells were incubated with different concentrations (μg/mL) of grape pomace extract and cell viability was determined after incubation with propidium iodide through efflux cytometry assay. As controls, HeLa cells were incubated without treatment (CC); with the solvent used with the extract (CS); \*t-test \*(P \<0.002), \*\* (P \<0.001) *v/s* CC.](pone.0172273.g001){#pone.0172273.g001}

The same analysis was done with combinations of grape pomace extract with ciprofloxacin, chloramphenicol and ampicillin, using the minimum concentration of extract (47 μg/mL) in which a synergistic effect was observed. Concentrations used for the tested antibiotics are shown in [Table 6](#pone.0172273.t006){ref-type="table"}. Antibiotics alone or combined with the grape pomace extract were non-toxic to HeLa cell line, at the concentrations tested and after 24 h incubation, showing no significant differences in the viability compared with the control. These results are promising for possible applications in animal models.

10.1371/journal.pone.0172273.t006

###### Cytotoxicity on HeLa cells by antibiotics alone and in combination with grape pomace extract.
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  Cell viability (%)                                                                                 
  -------------------- ------------ ------------ ------ ------------ ------------ ----- ------------ ------------
  0                    98.9 ± 0.9   99.1 ± 0.5   0      98.6 ± 0.4   97.5 ± 1.1   0     98.3 ± 0.8   98.7 ± 0.6
  0.62                 97.2 ± 1.8   96.6 ± 2.1   0.62   97.1 ± 0.5   98.4 ± 0.6   23    98.1 ± 0.6   97.3 ±1.8
  1.25                 97.5 ± 0.8   97.4 ± 2.2   1.25   96.2 ± 0.4   96.2 ± 0.2   47    97.3 ± 0.7   95.7 ± 1.9
  2.5                  98.7 ± 1.4   98.6 ± 0.4   2.5    93.8 ± 1.4   95.7 ± 0.8   94    97.8 ± 0.9   96.6 ± 0.4
  5                    98.4 ± 0.9   98.6 ± 0.8   5      93.2 ± 1.4   96.4 ± 0.1   188   97.6 ± 0.4   98.4 ± 0.4
  10                   97.6 ± 1.3   98.8 ± 1.3   10     95.4 ± 1.1   96.7 ± 0.5   375   97.4 ± 0.7   97.8 ± 0.5
  20                   97.0 ± 2.3   97.9 ± 1.1   20     96.5 ± 1.1   98.3 ± 0.9   750   96.7 ± 1.1   97.4 ± 0.8

\*The concentration of the grape pomace extract was 47 μg/mL; t-test P ˃ 0.05.

Conclusions {#sec017}
===========

Grape pomace extract obtained from Cabernet sauvignon variety, used in combination with antibiotics of different classes against *S*. *aureus* and *E*. *coli* strains, especially multi-drug resistant clinical isolates, showed synergy reducing significantly the MICs of different classes of antibiotics studied in this work. This synergistic effect may be due to the joint action of the compounds contained in the extract, and not to a particular compound. Moreover, pomace extract--antibiotic combinations are not toxic for the HeLa cell line at concentrations in which the synergistic effect was determined. Therefore, these mixtures are good candidates for animal model testing in order to enhance the effect of antibiotics of different classes and thus restore the currently unused agents due to the phenomenon of resistance. Furthermore, the use of grape pomace is a good alternative for this purpose as being a residue of the wine industry, so that extracts and/or phenolic compounds could be obtained from this waste at low cost.
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